CNS Drugs

PEER-REVIEWED FEATURE

Dextromethorphan/Bupropion: Adis Evaluation

Key points

- An uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist (dextromethorphan) co-formulated with an aminoketone and CYP2D6 inhibitor (which increases dextromethorphan bioavailability) is being developed by Axsome Therapeutics, Inc. for use in the treatment of CNS conditions
- Received its first approval on 18 August 2022 in the USA
- Approved for use in the treatment of MDD in adults

Summary

An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist] and the antidepressant bupropion hydrochloride (an aminoketone and CYP2D6 inhibitor that increases dextromethorphan bioavailability) [AUVELITYTM; dextromethorphan/bupropion], is being developed by Axsome Therapeutics, Inc. for the treatment of major depressive disorder (MDD), Alzheimer's disease agitation and smoking cessation.

Dextromethorphan/bupropion was approved in the USA in August 2022 for the treatment of MDD in adults.